Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.

Ballatore C, Brunden KR, Piscitelli F, James MJ, Crowe A, Yao Y, Hyde E, Trojanowski JQ, Lee VM, Smith AB 3rd.

J Med Chem. 2010 May 13;53(9):3739-47. doi: 10.1021/jm100138f.

2.

Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Ballatore C, Brunden KR, Huryn DM, Trojanowski JQ, Lee VM, Smith AB 3rd.

J Med Chem. 2012 Nov 8;55(21):8979-96. doi: 10.1021/jm301079z. Epub 2012 Sep 28. Review.

3.

Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.

Ballatore C, Brunden KR, Trojanowski JQ, Lee VM, Smith AB 3rd, Huryn DM.

Curr Top Med Chem. 2011;11(3):317-30. Review.

4.

Transgenic mouse models of tauopathy in drug discovery.

Noble W, Hanger DP, Gallo JM.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):403-28. Review.

PMID:
20522014
5.

Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.

Brunden KR, Ballatore C, Lee VM, Smith AB 3rd, Trojanowski JQ.

Biochem Soc Trans. 2012 Aug;40(4):661-6. doi: 10.1042/BST20120010. Review.

6.

Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.

Brunden KR, Ballatore C, Crowe A, Smith AB 3rd, Lee VM, Trojanowski JQ.

Exp Neurol. 2010 Jun;223(2):304-10. doi: 10.1016/j.expneurol.2009.08.031. Epub 2009 Sep 8. Review.

7.

Further understanding of tau phosphorylation: implications for therapy.

Medina M, Avila J.

Expert Rev Neurother. 2015 Jan;15(1):115-22. doi: 10.1586/14737175.2015.1000864. Epub 2015 Jan 2. Review.

PMID:
25555397
8.

Tau phosphorylation and aggregation as a therapeutic target in tauopathies.

Badiola N, Suárez-Calvet M, Lleó A.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):727-40. Review.

PMID:
20942789
9.

Invited review: Drug development for tauopathies.

Grüninger F.

Neuropathol Appl Neurobiol. 2015 Feb;41(1):81-96. doi: 10.1111/nan.12192. Review.

PMID:
25354646
10.

Development of tau aggregation inhibitors for Alzheimer's disease.

Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E.

Angew Chem Int Ed Engl. 2009;48(10):1740-52. doi: 10.1002/anie.200802621. Review.

PMID:
19189357
11.

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.

Navarrete LP, Pérez P, Morales I, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):678-85. Review.

PMID:
21605038
12.

Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies.

Julien C, Bretteville A, Planel E.

Methods Mol Biol. 2012;849:473-91. doi: 10.1007/978-1-61779-551-0_32. Review.

PMID:
22528110
13.

Biochemistry and molecular biology of tauopathies.

Hasegawa M.

Neuropathology. 2006 Oct;26(5):484-90. Review.

PMID:
17080729
14.

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.

Hanger DP, Anderton BH, Noble W.

Trends Mol Med. 2009 Mar;15(3):112-9. doi: 10.1016/j.molmed.2009.01.003. Epub 2009 Feb 24. Review.

PMID:
19246243
15.

Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies.

Pasinetti GM, Ksiezak-Reding H, Santa-Maria I, Wang J, Ho L.

J Neurochem. 2010 Sep;114(6):1557-68. doi: 10.1111/j.1471-4159.2010.06875.x. Epub 2010 Jul 27. Review.

16.

Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice.

Michaelis ML, Georg G, Telikepalli H, McIntosh M, Rajewski RA.

Curr Alzheimer Res. 2006 Jul;3(3):215-9. Review. Erratum in: Curr Alzheimer Res. 2009 Jun;6(3):320. Georg, G [added]; Telikepalli, H [added]; McIntosh, M [added]; Rajewski, R A [added].

PMID:
16842098
17.

The role of tau in Alzheimer's disease.

Trojanowski JQ, Lee VM.

Med Clin North Am. 2002 May;86(3):615-27. Review.

PMID:
12168561
18.

Animal models of tauopathies.

Higuchi M, Saido TC, Suhara T.

Neuropathology. 2006 Oct;26(5):491-7. Review.

PMID:
17080730
19.

Current strategies for the treatment of Alzheimer's disease and other tauopathies.

Dickey CA, Petrucelli L.

Expert Opin Ther Targets. 2006 Oct;10(5):665-76. Review.

PMID:
16981824
20.

Neurodegenerative tauopathies.

Lee VM, Goedert M, Trojanowski JQ.

Annu Rev Neurosci. 2001;24:1121-59. Review.

PMID:
11520930

Supplemental Content

Support Center